Show simple item record

dc.contributor.authorWatt, Matthew J
dc.contributor.authorClark, Ashlee K
dc.contributor.authorSelth, Luke A
dc.contributor.authorHaynes, Vanessa R
dc.contributor.authorLister, Natalie
dc.contributor.authorRebello, Richard
dc.contributor.authorPorter, Laura H
dc.contributor.authorNiranjan, Birunthi
dc.contributor.authorWhitby, Sarah T
dc.contributor.authorLo, Jennifer
dc.contributor.authorHuang, Cheng
dc.contributor.authorSchittenhelm, Ralf B
dc.contributor.authorAnderson, Kimberley E
dc.contributor.authorFuric, Luc
dc.contributor.authorWijayaratne, Poornima R
dc.contributor.authorMatzaris, Maria
dc.contributor.authorMontgomery, Magdalene K
dc.contributor.authorPapargiris, Melissa
dc.contributor.authorNorden, Sam
dc.contributor.authorFebbraio, Maria
dc.contributor.authorRisbridger, Gail P
dc.contributor.authorFrydenberg, Mark
dc.contributor.authorNomura, Daniel K
dc.contributor.authorTaylor, Renea A
dc.date.accessioned2019-09-11T09:09:13Z
dc.date.available2019-09-11T09:09:13Z
dc.date.issued2019en
dc.identifier.citationWatt MJ, Clark AK, Selth LA, Haynes VR, Lister N, Rebello R, et al. Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer. Sci Transl Med. 2019 Feb 6;11(478).en
dc.identifier.pmid30728288en
dc.identifier.doi10.1126/scitranslmed.aau5758en
dc.identifier.urihttp://hdl.handle.net/10541/621989
dc.description.abstractMetabolism alterations are hallmarks of cancer, but the involvement of lipid metabolism in disease progression is unclear. We investigated the role of lipid metabolism in prostate cancer using tissue from patients with prostate cancer and patient-derived xenograft mouse models. We showed that fatty acid uptake was increased in human prostate cancer and that these fatty acids were directed toward biomass production. These changes were mediated, at least partly, by the fatty acid transporter CD36, which was associated with aggressive disease. Deleting Cd36 in the prostate of cancer-susceptible Pten(-/-) mice reduced fatty acid uptake and the abundance of oncogenic signaling lipids and slowed cancer progression. Moreover, CD36 antibody therapy reduced cancer severity in patient-derived xenografts. We further demonstrated cross-talk between fatty acid uptake and de novo lipogenesis and found that dual targeting of these pathways more potently inhibited proliferation of human cancer-derived organoids compared to the single treatments. These findings identify a critical role for CD36-mediated fatty acid uptake in prostate cancer and suggest that targeting fatty acid uptake might be an effective strategy for treating prostate cancer.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1126/scitranslmed.aau5758en
dc.titleSuppressing fatty acid uptake has therapeutic effects in preclinical models of prostate canceren
dc.typeArticleen
dc.contributor.departmentDepartment of Physiology, University of Melbourne, Melbourne, VIC 3010, Australiaen
dc.identifier.journalScience Translational Medicineen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record